SBIR Phase II: Production of an affordable synthetic colostrum replacer in edible green algae

SBIR 第二阶段：用可食用绿藻生产经济实惠的合成初乳替代品

• 批准号: 1555951
• 负责人: Miller Tran
• 金额: $ 71.26万
• 依托单位: Triton Animal Products
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-01 至 2018-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1555951&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Production; affordable

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project will be to produce colostrum proteins in edible green algae that have the potential to reduce the use and dependence on antibiotics in livestock animals. Colostrum proteins have both beneficial health and growth properties that may drastically decrease the dependence on antibiotics. Unfortunately, there is a limited supply of colostrum. Algae provide an affordable and scalable system for the production of the valuable proteins found in colostrum. Recently, it was demonstrated that the use of antibiotics in livestock animals caused the formation of antibiotic resistant bacteria. Colostrum proteins naturally stimulate the animal's immune system and allows them to improve their own ability to fight off infections and ultimately increase their rate of weight gain. The production of colostrum proteins at a large scale in an untapped market that has the potential to gain market share from the multi-billion dollar antibiotic industry. This SBIR Phase II project proposes to demonstrate the feasibility of producing colostrum proteins in algae using biomanufacturing. Some of the problems associated with having the animal livestock industry adapt a new product is demonstrating cost and feasibility. To accomplish the goal of decreasing antibiotic use, this project will first focus on optimizing the production process to drive the cost of producing colostrum proteins in algae down. Next, work will be done on developing optimal formulations of colostrum proteins and testing them in mice models before moving to larger livestock animals. Once an optimal formulation is established, trials will be done in pig models. In the pig models, colostrum proteins produced in algae will be tested to determine their ability to assist animals in fighting off infections and also their ability to improve the animal's rate of weight gain. Finally, this project will strive to demonstrate that colostrum proteins produced in algae can give the same positive outcomes in animals when compared to animals given antibiotics. By accomplishing these goals, algae colostrum proteins can drastically decrease the dependence on antibiotics and their negative side effects.

这项小企业创新研究（SBIR）二期项目的更广泛影响/商业潜力将是在食用绿藻中生产初乳蛋白，这有可能减少牲畜对抗生素的使用和依赖。初乳蛋白具有有益健康和生长的特性，可以大大减少对抗生素的依赖。不幸的是，初乳的供应有限。藻类为生产初乳中发现的有价值的蛋白质提供了一种经济实惠且可扩展的系统。最近，有研究表明，在家畜中使用抗生素会导致耐药细菌的形成。初乳蛋白能天然地刺激动物的免疫系统，提高它们自身抵抗感染的能力，最终提高它们的增重速度。在一个尚未开发的市场上大规模生产初乳蛋白，有可能从数十亿美元的抗生素行业中获得市场份额。本SBIR二期项目旨在证明利用生物制造技术在藻类中生产初乳蛋白的可行性。与畜牧行业适应新产品相关的一些问题是证明成本和可行性。为了实现减少抗生素使用的目标，本项目首先将重点优化生产工艺，以降低藻类初乳蛋白的生产成本。下一步，将开发初乳蛋白的最佳配方，并在小鼠模型中进行测试，然后再转移到更大的牲畜身上。一旦确定了最佳配方，将在猪模型中进行试验。在猪模型中，将测试藻类中产生的初乳蛋白，以确定它们帮助动物抵抗感染的能力，以及它们提高动物增重速度的能力。最后，该项目将努力证明，与使用抗生素的动物相比，藻类中产生的初乳蛋白可以给动物带来相同的积极结果。通过实现这些目标，藻类初乳蛋白可以大大减少对抗生素的依赖及其副作用。